Diametric Capital »

Crispr Therapeutics shares owned by Diametric Capital

Quarter-by-quarter ownership of Crispr Therapeutics (CRSP) shares owned by Diametric Capital from 13F filings

Historical chart of Diametric Capital investment in Crispr Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Crispr Therapeutics held by Diametric Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Crispr Therapeutics by Diametric Capital

Quarter filed Position value Share count Share price at filing
2026-06-30 $349k 6.4k 54.54

More positions owned by Diametric Capital

State Str Spdr S&p 500 Etf T Tr Unit (SPY)
Precigen (PGEN)
Invesco Exch Traded Fd Tr Ii S&p500 Low Vol (SPLV)
Fulgent Genetics (FLGT)
Ishares Tr Msci Eafe Etf (EFA)
A2z Cust2mate Solutions Corp (AZ)
Uniqure Nv SHS (QURE)
Liquidia Corporation Com New (LQDA)
Almonty Inds Com New (ALM)
Golar Lng SHS (GLNG)
Calumet (CLMT)
Abivax Sa Sponsored Ads (ABVX)
Digital Realty Trust (DLR)
Telephone & Data Sys Com New (TDS)
MGM Resorts International. (MGM)

View all positions for Diametric Capital

Top funds holding Crispr Therapeutics

ARK Investment Management
BlackRock
Orbis Allan Gray
Capital World Investors
State Street Corporation
GSK
Geode Capital Management
Sr One Capital Management
Two Sigma Investments
FMR
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
EcoR1 Capital
UBS Group
Capital Research and Management Company - Division 3

View all funds holding Crispr Therapeutics